Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Large ribosomal subunit protein mL45, mitochondrial (MRPL45), is a nuclear-encoded protein that becomes a constituent of the 39S large subunit of the mitochondrial ribosome. It facilitates mitochondrial translation by directing nascent polypeptides to the exit tunnel, ensuring proper passage and membrane association for co-translational protein insertion into the mitochondrial inner membrane. MRPL45 exhibits functional and sequence homology with yeast Mba1 and shares characteristics with Tim44, reflecting its evolutionary origins from alpha-proteobacteria. MRPL45 is essential for mitochondrial protein synthesis, with unique and non-redundant roles; loss of function usually results in profound cellular and developmental defects. Disruption of MRPL45 or other mitochondrial ribosomal proteins is linked to a spectrum of human diseases, mostly related to defects in cellular energy metabolism and mitochondrial translation, but MRPL45 is not a recognized or direct therapeutic target nor is it targeted by currently approved drugs.
As MRPL45 is a structural protein, there are no mechanisms of action described for drugs targeting it.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Large ribosomal subunit protein mL45, mitochondrial (MRPL45).